MedTrace Logo

Systematic and Mechanism-based Approach to Rational Treatment Trials of Blood Cancer

NCT03488641 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2021-12-01

No results posted yet for this study

Summary

This observational study evaluates if drug response testing can be performed within 7 days and analyzes the value of ex-vivo drug screening for hematological malignancies as a biomarker to predict outcome, clinical course and response to treatment.

Conditions

Interventions

DIAGNOSTIC_TEST

ex-vivo drug response assay

drug sensitivity testing of primary patient derived cancer cells

Sponsors & Collaborators

  • University Hospital Heidelberg

    collaborator OTHER

  • German Cancer Research Center

    lead OTHER

Principal Investigators

  • Sascha Dietrich, MD · University Hospital Heidelberg and DKFZ

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-16
Primary Completion
2021-07-30
Completion
2021-08-02

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03488641 on ClinicalTrials.gov